CN100432047C - Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus - Google Patents

Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus Download PDF

Info

Publication number
CN100432047C
CN100432047C CNB2006100363265A CN200610036326A CN100432047C CN 100432047 C CN100432047 C CN 100432047C CN B2006100363265 A CNB2006100363265 A CN B2006100363265A CN 200610036326 A CN200610036326 A CN 200610036326A CN 100432047 C CN100432047 C CN 100432047C
Authority
CN
China
Prior art keywords
tert
ethyl
carboxylic acid
butyl
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2006100363265A
Other languages
Chinese (zh)
Other versions
CN1986521A (en
Inventor
方炳虎
陈建新
陈良柱
温志芬
曾振灵
廖明
陈杖榴
陈瑞爱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Winson Food Group Ltd By Share Ltd
South China Agricultural University
Original Assignee
South China Agricultural University
Guangdong Wens Foodstuff Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South China Agricultural University, Guangdong Wens Foodstuff Group Co Ltd filed Critical South China Agricultural University
Priority to CNB2006100363265A priority Critical patent/CN100432047C/en
Publication of CN1986521A publication Critical patent/CN1986521A/en
Application granted granted Critical
Publication of CN100432047C publication Critical patent/CN100432047C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to medicine compound, and discloses synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus. The present invention synthesizes peramivir with Wins lactam and 2-ethyl butyl aldehyde as main materials and through an eight-step process. The preparation process of the present invention is simple, cheap in material and environment friendly, and has high yield, including single step reaction yield of 80-95 % and total yield up to 52.7 %.

Description

一种抗流感及禽流感病毒药物帕拉米韦的合成方法 A kind of synthetic method of anti-influenza and avian influenza virus drug peramivir

技术领域 technical field

本发明涉及药物化合物领域,具体地说,涉及一种抗流感及禽流感病毒药物帕拉米韦的合成方法。The invention relates to the field of pharmaceutical compounds, in particular to a synthesis method of peramivir, an anti-influenza and avian influenza virus drug.

背景技术 Background technique

帕拉米韦,英文名称为peramivir,化学名称为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-胍基-t-2-羟基环戊基-1-羧酸,结构如式(I),是由美国BioCryst Pharmaceuticals公司与R.W.Johnson药物研究所联合开发的一种环戊烷衍生物类神经氨酸酶抑制剂。该药物能有效抑制各种流感病毒株的复制和传播过程,具有耐受性好、毒性小等优点,是一种很有应用前景的抗流感化疗药物。Peramivir, the English name is peramivir, the chemical name is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-guanidino-t-2-hydroxy Cyclopentyl-1-carboxylic acid, with a structure such as formula (I), is a cyclopentane derivative neuraminidase inhibitor jointly developed by the American BioCryst Pharmaceuticals company and the R.W.Johnson Institute of Drug Research. The drug can effectively inhibit the replication and transmission process of various influenza virus strains, has the advantages of good tolerance, low toxicity, etc., and is a very promising anti-influenza chemotherapeutic drug.

Figure C20061003632600051
Figure C20061003632600051

当前帕拉米韦的合成制备方法主要有BioCryst Pharmaceuticals公司的专利(International Patent Application PCT/US98126871,17Dec,1998.WO99/33781,08July,1999)。The current synthetic preparation method of peramivir mainly contains the patent of BioCryst Pharmaceuticals (International Patent Application PCT/US98126871, 17Dec, 1998.WO99/33781, 08July, 1999).

BioCryst Pharmaceuticals公司专利方法的化学反应式如下所示:The chemical reaction formula of BioCryst Pharmaceuticals' patented method is as follows:

Figure C20061003632600061
Figure C20061003632600061

该方法是利用文斯内酰胺为原料,经过长达十多步的反应得到终产物,不仅步骤长,产率低(总产率不足30%),而且在催化氢化过程中使用昂贵的二氧化铂作催化剂,在制备醛肟时使用了剧毒的苯氰,并以苯作溶剂,成本高昂,环保要求高,操作难度大,不适于工业化生产。The method is to use Wens lactam as a raw material to obtain the final product through more than ten steps of reaction. Not only the steps are long and the yield is low (the total yield is less than 30%), but also expensive carbon dioxide is used in the catalytic hydrogenation process. Platinum is used as a catalyst, and highly toxic benzene cyanide is used in the preparation of aldoxime, and benzene is used as a solvent. The cost is high, the environmental protection requirements are high, the operation is difficult, and it is not suitable for industrial production.

发明内容 Contents of the invention

本发明的目的是克服现有帕拉米韦合成方法中存在的问题,提供一种步骤简单,成本低廉,安全环保的帕拉米韦合成方法。The purpose of the present invention is to overcome the problems existing in the existing peramivir synthesis method, and provide a peramivir synthesis method with simple steps, low cost, safety and environmental protection.

为了实现上述目的,本发明采用如下合成方法:In order to achieve the above object, the present invention adopts following synthetic method:

Figure C20061003632600071
Figure C20061003632600071

具体步骤如下:Specific steps are as follows:

1.将文斯内酰胺溶入无水甲醇中,然后室温下持续通干燥的HCl气体2小时,再加热至45℃搅拌1小时。反应完全后浓缩、结晶,过滤、干燥得白色固体。此固体为(±)-cis-4-氨基环戊-2-烯-1-羧酸甲酯的盐酸盐。1. Dissolve Wens lactam in anhydrous methanol, then continue to pass dry HCl gas at room temperature for 2 hours, then heat to 45°C and stir for 1 hour. After the reaction was complete, it was concentrated, crystallized, filtered and dried to obtain a white solid. This solid was the hydrochloride salt of methyl (±)-cis-4-aminocyclopent-2-ene-1-carboxylate.

2.将(±)-cis-4-氨基环戊-2-烯-1-羧酸甲酯的盐酸盐、NaHCO3、BOC2O的混合物,投入到二氯甲烷中,摩尔比为1∶0.5~2∶1~1.5。室温搅拌3小时。反应过成中有气体排出。反应毕,有机层依次水洗,饱和食盐水洗,无水Na2SO4干燥。蒸出溶剂后,得油状物。以正己烷∶乙酸乙酯=95∶5的混合溶液重结晶,得白色晶体产物(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯。2. Put the mixture of (±)-cis-4-aminocyclopent-2-ene-1-carboxylic acid methyl ester hydrochloride, NaHCO 3 , BOC 2 O into dichloromethane at a molar ratio of 1 : 0.5~2: 1~1.5. Stir at room temperature for 3 hours. Gas was released during the reaction. After the reaction, the organic layer was washed successively with water and saturated brine, and dried over anhydrous Na 2 SO 4 . After distilling off the solvent, an oil was obtained. Recrystallized from a mixed solution of n-hexane:ethyl acetate=95:5 to obtain (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester as white crystals.

3.将盐酸羟胺盐和碳酸钾溶于水中,等不再有气泡产生后,冰浴下慢慢滴加2-乙基丁醛的乙醇(99%)溶液。滴加完毕后,室温下搅拌2小时。然后用冰水稀释,以乙醚提取,有机相经水洗,饱和食盐水洗,无水NaSO4干燥后,浓缩得无色油状产物2-乙基-丁醛肟。3. Dissolve hydroxylamine hydrochloride and potassium carbonate in water, and after there are no more bubbles, slowly add the ethanol (99%) solution of 2-ethylbutyraldehyde dropwise under ice bath. After the dropwise addition was completed, the mixture was stirred at room temperature for 2 hours. Then it was diluted with ice water, extracted with ether, the organic phase was washed with water, washed with saturated brine, dried over anhydrous NaSO 4 , and concentrated to give 2-ethyl-butyraldehyde oxime as a colorless oily product.

4.将(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯,2-乙基-丁醛肟,按摩尔比1∶3.5~7投入到二氯甲烷中,在冰浴,避光条件下慢慢滴加NaOCl(9.4%)溶液。滴加完毕后继续反应0.5h,然后加热至室温反应7h。反应完全后,水洗,水相以二氯甲烷萃取两次。合并有机相,依次水洗,无水Na2SO4干燥,减压浓缩得粘稠液体。再以石油醚∶乙酸乙酯(90∶10)的混合溶剂重结晶,得白色晶体。4. Put (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester, 2-ethyl-butyraldehyde oxime in molar ratio of 1:3.5~7 In dichloromethane, NaOCl (9.4%) solution was slowly added dropwise in an ice bath and protected from light. After the dropwise addition, the reaction was continued for 0.5h, and then heated to room temperature for 7h. After the reaction was complete, it was washed with water, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, washed with water successively, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure to obtain a viscous liquid. Then it was recrystallized from a mixed solvent of petroleum ether: ethyl acetate (90:10) to obtain white crystals.

5.将上述产物转入氢化反应瓶中,加入氢化催化剂(PtO2或钯-活性炭),浓盐酸和甲醇,在加压下轻微加热氢化。氢化毕,吹N2半小时,将产物过硅藻土,滤液经减压蒸馏去除溶剂,真空干燥得无色或淡黄色固体,即为(±)-t-3-(1’-氨基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐。5. Transfer the above product into a hydrogenation reaction bottle, add a hydrogenation catalyst (PtO 2 or palladium-activated carbon), concentrated hydrochloric acid and methanol, and slightly heat hydrogenation under pressure. After hydrogenation, blow N for half an hour, pass the product through diatomaceous earth, distill the filtrate under reduced pressure to remove the solvent, and dry in vacuo to obtain a colorless or light yellow solid, which is (±)-t-3-(1'-amino- 2'-Ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester hydrochloride.

将(±)-t-3-(1’-氨基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐溶于二氯甲烷中,加入无水乙酸酐,室温搅拌16h。反应毕,加入水,分出有机层,水相以二氯甲烷萃取多次,合并有机相,依次水洗、饱和食盐水洗,无水Na2SO4干燥,减压蒸馏去除溶剂得白色固体产物(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯。(±)-t-3-(1'-amino-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r-1-carboxylic acid The hydrochloride of methyl ester was dissolved in dichloromethane, anhydrous acetic anhydride was added, and stirred at room temperature for 16h. After the reaction was complete, water was added, the organic layer was separated, the aqueous phase was extracted several times with dichloromethane, the organic phases were combined, washed with water and saturated brine successively, dried over anhydrous Na 2 SO 4 , and evaporated under reduced pressure to remove the solvent to obtain a white solid product ( ±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester.

6.将上述产物溶入无水乙醚中,回流状态下通干燥的氯化氢气体0.5h,再室温搅拌10小时,过滤得白色或黄白色固体,即(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-氨基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐。6. Dissolve the above product in anhydrous ether, pass dry hydrogen chloride gas under reflux for 0.5h, stir at room temperature for 10 hours, and filter to obtain a white or yellowish white solid, namely (±)-t-3-(1'- Acetamido-2'-ethyl)butyl-c-4-amino-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester hydrochloride.

将此中间体与N,N-1,3-二叔丁氧羰基-2-甲基-2-异硫脲、氯化汞溶入DMF中,室温搅拌20小时。以乙酸乙酯稀释,产生白色沉淀,过滤,弃去滤渣,滤液经水洗、饱和食盐水洗、无水硫酸钠干燥,减压浓缩得黄色粘稠固体。以石油醚∶乙酸乙酯=3∶7~1∶1过柱分离得白色固体产物(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯。Dissolve this intermediate, N,N-1,3-di-tert-butoxycarbonyl-2-methyl-2-isothiourea and mercuric chloride in DMF, and stir at room temperature for 20 hours. Dilute with ethyl acetate to produce a white precipitate, filter, discard the filter residue, wash the filtrate with water and saturated brine, dry over anhydrous sodium sulfate, and concentrate under reduced pressure to obtain a yellow sticky solid. The white solid product (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4 was obtained by column separation with petroleum ether:ethyl acetate=3:7~1:1 -(N,N-1",3"-di-tert-butoxycarbonyl)guanidino-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester.

7.将(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯溶入(THF∶乙醇=1∶1)的混合溶剂中,再慢慢滴加1M的氢氧化钠溶液。室温搅拌3小时,蒸出溶剂,加入少许的水,以冰的1M的盐酸溶液调至弱酸性,再以乙酸乙酯萃取。所得有机相经水洗、饱和食盐水洗、无水硫酸钠干燥,浓缩得白色固体(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊烷-r-1-羧酸。7. Add (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1",3"-di-tert-butoxycarbonyl)guanidine Dissolve methyl-t-2-hydroxycyclopentyl-r-1-carboxylate in a mixed solvent (THF:ethanol=1:1), and slowly add 1M sodium hydroxide solution dropwise. Stir at room temperature for 3 hours, evaporate the solvent, add a little water, adjust to weak acidity with ice 1M hydrochloric acid solution, and extract with ethyl acetate. The obtained organic phase was washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to give a white solid (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-( N,N-1",3"-di-tert-butoxycarbonyl)guanidino-t-2-hydroxycyclopentane-r-1-carboxylic acid.

8.将上述产物、三氟乙酸、Et3SiH投入到二氯甲烷中,室温搅拌24小时,减压蒸出溶剂,所得干物质以乙醚洗,得黄色固体,再经甲醇∶水=1∶1的混合溶剂重结晶得白色晶体(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-胍基-t-2-羟基环戊基-1-羧酸,即帕拉米韦。8. Put the above product, trifluoroacetic acid, and Et 3 SiH into dichloromethane, stir at room temperature for 24 hours, distill off the solvent under reduced pressure, wash the obtained dry matter with ether to obtain a yellow solid, and then pass methanol: water = 1: 1 was recrystallized from a mixed solvent to obtain white crystals (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-guanidino-t-2-hydroxycyclopentyl- 1-Carboxylic acid, namely peramivir.

与现有技术相比,本发明采用如下有益效果:本发明针对现有帕拉米韦合成方法的不足,在催化氢化过程中改用了廉价的钯炭作催化剂,在制备醛肟过程中以乙醇和碳酸钾代替了剧毒的苯氰和苯,达到了降低生产成本、避免使用剧毒原料、减少污染的目的;合成步骤由现有的十多步变为八步,简化了合成步骤;另外,本发明合成方法的反应条件温和,设备简单,操作易行,产率高,单步反应达到80%~95%,总产率可达52.7%。Compared with the prior art, the present invention adopts the following beneficial effects: the present invention is aimed at the deficiencies of the existing peramivir synthetic method, and uses cheap palladium carbon as the catalyst in the catalytic hydrogenation process; Ethanol and potassium carbonate replaced highly toxic benzene cyanide and benzene, which achieved the purpose of reducing production costs, avoiding the use of highly toxic raw materials, and reducing pollution; the synthesis steps were changed from more than ten steps to eight steps, which simplified the synthesis steps; In addition, the synthesis method of the present invention has mild reaction conditions, simple equipment, easy operation and high yield. The single-step reaction reaches 80%-95%, and the total yield can reach 52.7%.

附图说明 Description of drawings

图1为(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯的1HNMR谱图;Fig. 1 is the 1 HNMR spectrogram of (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester;

图2为(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯的MS谱图;Fig. 2 is the MS spectrogram of (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester;

图3为(±)-4-叔丁氧碳酰胺基-3-(1’-乙基)丙基-4,5,6,6a-4H-3aH-环戊基[d]异噁唑-6-羧酸甲酯的1HNMR谱图;Figure 3 is (±)-4-tert-butoxycarbonamido-3-(1'-ethyl)propyl-4,5,6,6a-4H-3aH-cyclopentyl[d]isoxazole- 1 HNMR spectrum of methyl 6-carboxylate;

图4为(±)-4-叔丁氧碳酰胺基-3-(1’-乙基)丙基-4,5,6,6a-4H-3aH-环戊基[d]异噁唑-6-羧酸甲酯的MS谱图;Figure 4 is (±)-4-tert-butoxycarbonamido-3-(1'-ethyl)propyl-4,5,6,6a-4H-3aH-cyclopentyl[d]isoxazole- The MS spectrum of methyl 6-carboxylate;

图5为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的1HNMR谱图;Figure 5 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r- 1 HNMR spectrum of methyl 1-carboxylate;

图6为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的MS谱图;Figure 6 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r- The MS spectrum of 1-methyl carboxylate;

图7为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯的1HNMR谱图;Figure 7 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl)guanidine The 1 HNMR spectrum of methyl-t-2-hydroxycyclopentyl-r-1-carboxylate;

图8为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯的MS谱图;Figure 8 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl)guanidine The MS spectrum of base-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester;

图9为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸的1HNMR谱图;Figure 9 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl)guanidine The 1 HNMR spectrum of base-t-2-hydroxycyclopentyl-r-1-carboxylic acid;

图10为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸的MS谱图;Figure 10 is (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl)guanidine The MS spectrum of base-t-2-hydroxycyclopentyl-r-1-carboxylic acid;

图11为帕拉米韦的1HNMR谱图;Figure 11 is the 1 HNMR spectrum of peramivir;

图12为帕拉米韦的MS谱图;Figure 12 is the MS spectrum of peramivir;

具体实施方式 Detailed ways

实施例1Example 1

1.在带磁力搅拌,回流冷凝管,干燥管的250ml的三口瓶中加入5克文斯内酰胺,50ml甲醇,然后室温下持续通干燥的HCl气体2小时,再加热至45℃搅拌2小时。减压蒸馏去除溶剂得淡黄色粘稠物,向该粘稠物中加入100ml乙醚,室温搅拌2小时,析出白色沉淀,过滤、干燥得白色固体产物。此固体即是(±)-cis-4-氨基环戊-2-烯-1-羧酸甲酯的盐酸盐。1. Add 5 grams of Vince lactam and 50 ml of methanol into a 250ml three-neck flask with magnetic stirring, reflux condenser, and drying tube, then continue to pass dry HCl gas at room temperature for 2 hours, then heat to 45°C and stir for 2 hours. The solvent was distilled off under reduced pressure to obtain a light yellow viscous substance. 100 ml of diethyl ether was added to the viscous substance, and stirred at room temperature for 2 hours. A white precipitate precipitated out, which was filtered and dried to obtain a white solid product. This solid is the hydrochloride salt of methyl (±)-cis-4-aminocyclopent-2-ene-1-carboxylate.

产量7.7克,收率:95.2%Yield 7.7 g, Yield: 95.2%

2.将所得盐酸盐2.05克(11.5mmol),NaHCO30.81克(8.1mmol),BOC2O2.61克(11.9mmol),二氯甲烷50ml,投入到250ml的圆底烧瓶中,然后室温搅拌3小时。薄层色谱监视反应终点。反应毕,水洗,分出有机层,水层以二氯甲烷萃取两次,合并有机相,经水洗,饱和食盐水洗,无水Na2SO4干燥,减压蒸出溶剂后,得油状物。将此油状物用正己烷∶乙酸乙酯=95∶5的混合溶液淋洗,得白色晶体即为(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯(1)。2. 2.05 grams (11.5mmol) of gained hydrochloride, NaHCO 3 0.81 grams (8.1mmol), BOC 2 O2.61 grams (11.9mmol), methylene chloride 50ml, drop in the round bottom flask of 250ml, then room temperature Stir for 3 hours. Thin-layer chromatography monitored the reaction endpoint. After the reaction was completed, wash with water, separate the organic layer, extract the aqueous layer twice with dichloromethane, combine the organic phases, wash with water, wash with saturated brine, dry over anhydrous Na 2 SO 4 , and evaporate the solvent under reduced pressure to obtain an oily substance. The oil was rinsed with a mixed solution of n-hexane: ethyl acetate = 95:5 to obtain white crystals (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylate acid methyl ester (1).

产量:2.62克,收率:94.6%Yield: 2.62 g, Yield: 94.6%

熔点:36℃Melting point: 36°C

元素分析:C12H19NO4    M.W.:241.12Elemental analysis: C 12 H 19 NO 4 MW: 241.12

计算值:C 59.72  H 7.88  N 5.80  O 26.54Calculated: C 59.72 H 7.88 N 5.80 O 26.54

分析值:C 59.57  H 8.62  N 5.65  O 26.31Analytical value: C 59.57 H 8.62 N 5.65 O 26.31

该产物的1HNMR和MS谱图为图1,图2。The 1 HNMR and MS spectra of the product are shown in Fig. 1 and Fig. 2 .

3.先将3.0克的盐酸羟胺盐溶于25ml的水中,再向其中加入4克的碳酸钾。等不再有气泡产生后,冰浴下慢慢滴加2-乙基丁醛(4克)的乙醇(99%)溶液25ml。滴加完毕后,室温下搅拌1小时。然后用冰水稀释至500ml,以乙醚提取三次,再水洗,饱和食盐水洗,无水NaSO4干燥,浓缩得无色油状物3克,即2-乙基丁醛肟。3. Dissolve 3.0 grams of hydroxylamine hydrochloride in 25 ml of water, and then add 4 grams of potassium carbonate therein. After no more bubbles were generated, 25 ml of a solution of 2-ethylbutyraldehyde (4 g) in ethanol (99%) was slowly added dropwise under an ice bath. After the dropwise addition was completed, the mixture was stirred at room temperature for 1 hour. It was then diluted to 500ml with ice water, extracted three times with ether, washed with water, washed with saturated brine, dried over anhydrous NaSO 4 , and concentrated to give 3 g of a colorless oily substance, namely 2-ethylbutyraldehyde oxime.

4.将(1)5.18克(0.021mol),2-乙基丁醛肟7.25克(0.063mol),投入到20.7ml的二氯甲烷中,在冰浴下,慢慢滴加NaOCl(9.4%)38.6克(0.048mol)溶液。滴加完毕后继续反应半小时,然后加热至室温反应8小时。薄层色谱监视反应终点。反应毕,分出有机相,水相以乙酸乙酯萃取两次。合并有机相,水洗,无水Na2SO4干燥,减压浓缩。以石油醚∶乙酸乙酯(90∶10)的混合溶剂重结晶,得7.1克白色晶体,即为(±)-4-叔丁氧碳酰胺基-3-(1’-乙基)丙基-4,5,6,6a-4H-3aH-环戊基[d]异噁唑-6-羧酸甲酯(3)。产率:95.4%4. Put 5.18 grams (0.021mol) of (1) and 7.25 grams (0.063mol) of 2-ethylbutyraldehyde oxime into 20.7ml of dichloromethane, and slowly add NaOCl (9.4% ) 38.6 g (0.048 mol) solution. After the dropwise addition, the reaction was continued for half an hour, and then heated to room temperature for 8 hours. Thin-layer chromatography monitored the reaction endpoint. After the reaction was completed, the organic phase was separated, and the aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, washed with water, dried over anhydrous Na 2 SO 4 , and concentrated under reduced pressure. Recrystallize from a mixed solvent of petroleum ether: ethyl acetate (90:10) to obtain 7.1 g of white crystals, namely (±)-4-tert-butoxycarbonamido-3-(1'-ethyl)propyl -4,5,6,6a-methyl 4H-3aH-cyclopentyl[d]isoxazole-6-carboxylate (3). Yield: 95.4%

熔点:107~108℃Melting point: 107~108℃

元素分析:C18H30N2O5    M.W.:354.21Elemental analysis: C 18 H 3 0N 2 O 5 MW: 354.21

计算值:C 60.98  H 8.47  N 7.90    O 22.58Calculated: C 60.98 H 8.47 N 7.90 O 22.58

分析值:C 60.29  H 8.32  N 7.75    O 22.41Analytical value: C 60.29 H 8.32 N 7.75 O 22.41

该产物的1HNMR和MS谱图为图3,图4。 The 1 HNMR and MS spectra of the product are shown in Fig. 3 and Fig. 4 .

5.将(3)1克(2.8mmol)、钯-炭0.156克、甲醇95.2ml转入氢化反应瓶中,再加0.5ml的浓盐酸,在100~150psi的氢气氛围中,恒温45℃下剧烈搅拌24小时,冷却至室温,吹N2半小时,过硅藻土,浓缩,真空干燥得无色或淡黄固体1.09克,即为(±)-t-3-(1’-氨基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐。5. Transfer 1 g (2.8 mmol) of (3), 0.156 g of palladium-carbon, and 95.2 ml of methanol into a hydrogenation reaction bottle, and then add 0.5 ml of concentrated hydrochloric acid, in a hydrogen atmosphere of 100 to 150 psi, at a constant temperature of 45°C Stir vigorously for 24 hours, cool to room temperature, blow N for half an hour, pass through diatomaceous earth, concentrate, and dry in vacuo to obtain 1.09 g of a colorless or light yellow solid, which is (±)-t-3-(1'-amino- 2'-Ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester hydrochloride.

将所得中间体1.09克(2.78mmol)溶于80ml的二氯甲烷中,再依次加入Et3N0.38ml、无水乙酸酐0.47ml,室温搅拌16h。反应毕,加入20ml水,分出有机层,水相以二氯甲烷20ml萃取三次,合并有机相,依次水洗、饱和食盐水洗,无水Na2SO4干燥,减压蒸馏去除溶剂,得1.06克白色固体,即为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯(5),产率:94.6%。1.09 g (2.78 mmol) of the obtained intermediate was dissolved in 80 ml of dichloromethane, and then 0.38 ml of Et 3 N and 0.47 ml of anhydrous acetic anhydride were added in sequence, and stirred at room temperature for 16 h. After the reaction was complete, 20ml of water was added, the organic layer was separated, the aqueous phase was extracted three times with 20ml of dichloromethane, the organic phases were combined, washed with water and saturated brine successively, dried over anhydrous Na 2 SO 4 , and the solvent was removed by distillation under reduced pressure to obtain 1.06 g White solid, namely (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl- Methyl r-1-carboxylate (5), yield: 94.6%.

熔点:119~121℃Melting point: 119~121℃

元素分析:C20H36N2O6    M.W.:400.26Elemental analysis: C 2 0H 36 N 2 O 6 MW: 400.26

计算值:C 59.96  H 8.99  N 6.99  O 23.98Calculated: C 59.96 H 8.99 N 6.99 O 23.98

分析值:C 59.67  H 8.72  N 7.05  O 23.81Analytical value: C 59.67 H 8.72 N 7.05 O 23.81

该产物的1HNMR和MS谱图为图5,图6。 The 1 HNMR and MS spectra of the product are shown in Fig. 5 and Fig. 6 .

6.在带有磁力搅拌,回流冷凝管的500ml的三口烧瓶中,加入1.5克(3.75mmol)的(5),200ml的乙醚。待全溶后,持续通干燥HCl气15分钟,室温搅拌10小时后,加热回流2小时。薄层色谱监测反应终点。反应毕,过滤,得白色固体即(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-氨基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐。6. Add 1.5 g (3.75 mmol) of (5) and 200 ml of diethyl ether into a 500 ml three-neck flask with magnetic stirring and a reflux condenser. After complete dissolution, continue to pass dry HCl gas for 15 minutes, stir at room temperature for 10 hours, and heat to reflux for 2 hours. The reaction endpoint was monitored by thin-layer chromatography. After the reaction is completed, filter to obtain a white solid (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-amino-t-2-hydroxycyclopentyl-r - the hydrochloride salt of methyl 1-carboxylate.

将所得盐酸盐1.1克(3.26mmol)、三乙胺0.85ml(8.45mmol)、1,3-二叔丁氧碳酰基-2-甲基-2-异硫脲0.94克(3.26mmol)、氯化汞0.88克(3.26mmol)加入到50ml的DMF中,室温搅拌16小时。反应毕,以五倍体积的乙酸乙酯稀释,析出白色沉淀,过滤,滤液经水洗、饱和食盐水洗、无水硫酸钠干燥,浓缩得黄色粘稠固体。以石油醚∶乙酸乙酯=3∶7~1∶1过柱分离得1.3克白色固体,即为(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯(6),收率83%。The resulting hydrochloride 1.1 grams (3.26mmol), triethylamine 0.85ml (8.45mmol), 1,3-di-tert-butoxycarbonyl-2-methyl-2-isothiourea 0.94 grams (3.26mmol), Mercury chloride 0.88 g (3.26 mmol) was added in 50 ml of DMF, and stirred at room temperature for 16 hours. After the reaction was completed, it was diluted with five times the volume of ethyl acetate to precipitate a white precipitate, which was filtered, and the filtrate was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a yellow sticky solid. Using petroleum ether: ethyl acetate = 3:7 ~ 1:1 to separate the column to obtain 1.3 g of white solid, which is (±)-t-3-(1'-acetamido-2'-ethyl)butyl -c-4-(N,N-1", 3"-di-tert-butoxycarbonyl)guanidino-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester (6), yield 83% .

熔点:167℃Melting point: 167°C

元素分析:C26H46N4O8    M.W.:542.56Elemental analysis: C 26 H 46 N 4 O 8 MW: 542.56

计算值:C 57.51  H 8.48  N 10.32  O 23.59Calculated: C 57.51 H 8.48 N 10.32 O 23.59

分析值:C 57.53  H 8.16  N 10.35  O 23.33Analytical value: C 57.53 H 8.16 N 10.35 O 23.33

该产物的1HNMR和MS谱图为图7,图8。 The 1 HNMR and MS spectra of the product are shown in Fig. 7 and Fig. 8 .

7.将(6)0.5克(0.9mmol)溶入13ml(THF∶乙醇=1∶1)的混合溶剂中,慢慢滴加1M的氢氧化钠溶液5ml(5mmmol),室温搅拌3小时,减压蒸馏去除溶剂,加入6ml的水,以冰的1M的盐酸溶液调至弱酸性,再以乙酸乙酯萃取。所得有机相经水洗、饱和食盐水洗、无水硫酸钠干燥,减压浓缩得0.45克白色固体,即(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸(7),产率:95%7. Dissolve 0.5 g (0.9 mmol) of (6) in a mixed solvent of 13 ml (THF: ethanol = 1: 1), slowly add 5 ml (5 mmmol) of 1M sodium hydroxide solution dropwise, stir at room temperature for 3 hours, reduce The solvent was distilled off under pressure, 6ml of water was added, adjusted to weak acidity with iced 1M hydrochloric acid solution, and then extracted with ethyl acetate. The obtained organic phase was washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 0.45 g of a white solid, namely (±)-t-3-(1'-acetamido-2'-ethyl)butyl -c-4-(N, N-1", 3"-di-tert-butoxycarbonyl)guanidino-t-2-hydroxycyclopentyl-r-1-carboxylic acid (7), yield: 95%

熔点:219~220℃Melting point: 219~220℃

元素分析:C25H44N4O8    M.W.:528.32Elemental analysis: C 25 H 44 N 4 O 8 MW: 528.32

计算值:C 56.78  H 8.33  N 10.60  O 24.23Calculated: C 56.78 H 8.33 N 10.60 O 24.23

分析值:C 56.67  H 8.12  N 10.55  O 24.31Analytical value: C 56.67 H 8.12 N 10.55 O 24.31

该产物的1HNMR和MS谱图为图9,图10。The 1 HNMR and MS spectra of the product are shown in Figure 9 and Figure 10 .

8.将(7)0.30克(0.56mmol)、三氟乙酸1.9ml、Et3SiH0.5ml投入到32ml的二氯甲烷中,室温搅拌12小时,减压蒸出溶剂,所得干物质以20ml的乙醚洗,得黄色固体0.17克。将此固体产物以三氯甲烷∶甲醇=7∶3~1∶1的混合溶液过硅胶柱,所得粗产物再以甲醇∶水=1∶1的混合溶液重结晶,得0.15克白色固体,即(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-胍基-t-2-羟基环戊基-1-羧酸(8),即为帕拉米韦。产率:82.3%8. Put 0.30 g (0.56 mmol) of (7), 1.9 ml of trifluoroacetic acid, and 0.5 ml of Et 3 SiH into 32 ml of dichloromethane, stir at room temperature for 12 hours, evaporate the solvent under reduced pressure, and obtain dry matter in 20 ml of After washing with ether, 0.17 g of a yellow solid was obtained. The solid product was passed through a silica gel column with a mixed solution of chloroform: methanol = 7: 3 ~ 1: 1, and the resulting crude product was recrystallized with a mixed solution of methanol: water = 1: 1 to obtain 0.15 g of a white solid, namely (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-guanidino-t-2-hydroxycyclopentyl-1-carboxylic acid (8), namely For peramivir. Yield: 82.3%

熔点:>251℃Melting point: >251°C

元素分析:C15H28N4O4    M.W.:328.24Elemental analysis: C 15 H 28 N 4 O 4 MW: 328.24

计算值:C 54.84  H 8.53  N 17.06  O 19.50Calculated: C 54.84 H 8.53 N 17.06 O 19.50

分析值:C 54.67  H 8.52  N 17.11  O 19.31Analytical value: C 54.67 H 8.52 N 17.11 O 19.31

该产物的1HNMR和MS谱图为图11,图12。The 1 HNMR and MS spectra of the product are shown in Figure 11 and Figure 12 .

Claims (9)

1.一种帕拉米韦的合成方法,其特征在于包括如下步骤:1. a synthetic method of peramivir, is characterized in that comprising the steps: (1)将文斯内酰胺溶于醇溶液中,在盐酸催化下开环酯化,制得(±)-cis-4-氨基环戊-2-烯-1-羧酸甲酯的盐酸盐,反应式如下(1) Dissolving Wens lactam in an alcoholic solution, catalyzed by hydrochloric acid for ring-opening esterification to obtain hydrochloric acid of (±)-cis-4-aminocyclopent-2-ene-1-carboxylic acid methyl ester salt, the reaction formula is as follows (2)将(±)-cis-4-氨基环戊-2-烯-1-羧酸甲酯的盐酸盐和二碳酸二叔丁酯投入碱性溶液与有机溶剂组成的两相体系中,剧烈搅拌反应,制得(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯,反应式如下:(2) Put (±)-cis-4-aminocyclopent-2-ene-1-carboxylic acid methyl ester hydrochloride and di-tert-butyl dicarbonate into a two-phase system composed of alkaline solution and organic solvent , Vigorously stirred and reacted to obtain (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester, the reaction formula is as follows:
Figure C2006100363260002C2
Figure C2006100363260002C2
(3)2-乙基丁醛在醇-碳酸盐体系中与盐酸羟氨盐反应制得2-乙基丁醛肟,反应式如下:(3) 2-ethylbutyraldehyde reacts with hydroxylammonium hydrochloride in the alcohol-carbonate system to prepare 2-ethylbutyraldehyde oxime, and the reaction formula is as follows: (4)将(±)-cis-4-叔丁氧碳酰胺基环戊-2-烯-1-羧酸甲酯和2-乙基丁醛肟投入到有机溶剂中,在碱催化下发生环加成反应,制得(±)-4-叔丁氧碳酰胺基-3-(1’-乙基)丙基-4,5,6,6a-4H-3aH-环戊基[d]异噁唑-6-羧酸甲酯,反应式如下:(4) Put (±)-cis-4-tert-butoxycarbonamidocyclopent-2-ene-1-carboxylic acid methyl ester and 2-ethylbutyraldehyde oxime into an organic solvent, and the reaction occurs under alkali catalysis. Cycloaddition reaction to produce (±)-4-tert-butoxycarbonamido-3-(1'-ethyl)propyl-4,5,6,6a-4H-3aH-cyclopentyl[d] Isoxazole-6-carboxylic acid methyl ester, the reaction formula is as follows:
Figure C2006100363260002C4
Figure C2006100363260002C4
(5)将(±)-4-叔丁氧碳酰胺基-3-(1’-乙基)丙基-4,5,6,6a-4H-3aH-环戊基[d]异噁唑-6-羧酸甲酯在醇溶液中催化氢化,制得(±)-t-3-(1’-氨基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐;再将所得产物经乙酰化,即生成中间产物(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯,反应式如下:(5) (±)-4-tert-butoxycarbonamido-3-(1'-ethyl)propyl-4,5,6,6a-4H-3aH-cyclopentyl[d]isoxazole - Catalytic hydrogenation of methyl 6-carboxylate in alcohol solution to obtain (±)-t-3-(1'-amino-2'-ethyl)butyl-c-4-tert-butoxycarbonamido- The hydrochloride salt of t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester; then the resulting product is acetylated to generate the intermediate product (±)-t-3-(1'-acetamido- 2'-Ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester, the reaction formula is as follows: (6)中间产物(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-叔丁氧碳酰胺基-t-2-羟基环戊基-r-1-羧酸甲酯在醚中脱BOC保护得(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-氨基-t-2-羟基环戊基-r-1-羧酸甲酯的盐酸盐;将所得产物与N,N-1,3-二叔丁氧羰基-2-甲基-2-异硫脲投入到无机盐和碱性有机溶剂组成的反应体系中,剧烈搅拌反应,制得(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯,反应式如下:(6) Intermediate product (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-tert-butoxycarbonamido-t-2-hydroxycyclopentyl- r-1-carboxylate methyl ester de-BOC protected in ether to get (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-amino-t-2- The hydrochloride salt of methyl hydroxycyclopentyl-r-1-carboxylate; put the obtained product and N,N-1,3-di-tert-butoxycarbonyl-2-methyl-2-isothiourea into inorganic salt In a reaction system composed of an alkaline organic solvent, the reaction is vigorously stirred to obtain (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N -1", 3"-di-tert-butoxycarbonyl)guanidine-t-2-hydroxycyclopentyl-r-1-carboxylate methyl ester, the reaction formula is as follows:
Figure C2006100363260003C2
Figure C2006100363260003C2
(7)将(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊基-r-1-羧酸甲酯投入到由醇、有机溶剂、氢氧化钠水溶液组成的反应体系中,制得(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊烷-r-1-羧酸,反应式如下:(7) (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl) Guanidino-t-2-hydroxycyclopentyl-r-1-carboxylic acid methyl ester is put into a reaction system composed of alcohol, organic solvent, and aqueous sodium hydroxide solution to obtain (±)-t-3-(1 '-Acetamido-2'-ethyl)butyl-c-4-(N,N-1",3"-di-tert-butoxycarbonyl)guanidino-t-2-hydroxycyclopentane-r- 1-carboxylic acid, the reaction formula is as follows: (8)将(±)-t-3-(1’-乙酰胺基-2’-乙基)丁基-c-4-(N,N-1”,3”-二叔丁氧羰基)胍基-t-2-羟基环戊烷-r-1-羧酸溶于惰性溶剂中,在有机强酸和有机硅烷催化下脱BOC即得到最终产物帕拉米韦,反应式如下:(8) (±)-t-3-(1'-acetamido-2'-ethyl)butyl-c-4-(N,N-1", 3"-di-tert-butoxycarbonyl) Guanidino-t-2-hydroxycyclopentane-r-1-carboxylic acid is dissolved in an inert solvent, and the final product peramivir is obtained by removing BOC under organic strong acid and organosilane catalysis, and the reaction formula is as follows:
Figure C2006100363260004C1
Figure C2006100363260004C1
2.按照权利要求1所述的合成方法,其特征在于步骤(1)所述醇为甲醇。2. according to the described synthetic method of claim 1, it is characterized in that the alcohol described in step (1) is methyl alcohol. 3.按照权利要求1所述的合成方法,其特征在于步骤(2)所述碱为NaHCO3或Na2CO3,所述有机溶剂为二氯甲烷或己烷。3. The synthesis method according to claim 1, characterized in that the base in step (2) is NaHCO 3 or Na 2 CO 3 , and the organic solvent is dichloromethane or hexane. 4.按照权利要求1所述的合成方法,其特征在于步骤(3)所述醇为甲醇或乙醇,所述碳酸盐为Na2CO3或K2CO34. The synthesis method according to claim 1, characterized in that the alcohol in step (3) is methanol or ethanol, and the carbonate is Na 2 CO 3 or K 2 CO 3 . 5.按照权利要求1所述的合成方法,其特征在于步骤(4)所述溶剂为二氯甲烷、己烷或庚烷,所述碱为三乙胺或次氯酸钠。5. according to the described synthetic method of claim 1, it is characterized in that the described solvent of step (4) is methylene dichloride, hexane or heptane, and described alkali is triethylamine or sodium hypochlorite. 6.按照权利要求1所述的合成方法,其特征在于步骤(5)所述醇为甲醇,所述催化剂为二氧化铂或钯-活性碳,所用酰化剂为乙酸酐。6. according to the described synthetic method of claim 1, it is characterized in that the described alcohol of step (5) is methyl alcohol, and described catalyzer is platinum dioxide or palladium-activated carbon, and used acylating agent is acetic anhydride. 7.按照权利要求1所述的合成方法,其特征在于步骤(6)所述醚为乙醚,所述无机盐为氯化汞,所述碱为三乙胺或乙二胺。7. according to the described synthetic method of claim 1, it is characterized in that the ether described in step (6) is ether, and described inorganic salt is mercuric chloride, and described alkali is triethylamine or ethylenediamine. 8.按照权利要求1所述的合成方法,其特征在于步骤(7)所述醇为乙醇,所述有机溶剂为四氢呋喃。8. according to the described synthetic method of claim 1, it is characterized in that the alcohol described in step (7) is ethanol, and described organic solvent is THF. 9.按照权利要求1所述的合成方法,其特征在于步骤(8)所述惰性溶剂为二氯甲烷,所述有机酸为三氟乙酸,所述有机硅烷为三乙基硅烷。9. according to the described synthetic method of claim 1, it is characterized in that the inert solvent described in step (8) is dichloromethane, and described organic acid is trifluoroacetic acid, and described organosilane is triethylsilane.
CNB2006100363265A 2006-07-03 2006-07-03 Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus Active CN100432047C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100363265A CN100432047C (en) 2006-07-03 2006-07-03 Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100363265A CN100432047C (en) 2006-07-03 2006-07-03 Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus

Publications (2)

Publication Number Publication Date
CN1986521A CN1986521A (en) 2007-06-27
CN100432047C true CN100432047C (en) 2008-11-12

Family

ID=38183477

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100363265A Active CN100432047C (en) 2006-07-03 2006-07-03 Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus

Country Status (1)

Country Link
CN (1) CN100432047C (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367750B (en) 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1S,2S,3S,4R)-3-[(1S)-1-acet-ammonia-2-ethyl-butyl]-4- guanidino-2-hydroxyl-cyclopentyl-1-carboxylic acid aqua compound and medical uses thereof
KR101064067B1 (en) * 2008-10-28 2011-09-08 (주)아모레퍼시픽 Perfume composition which reproduced scent of silk flower
CN102584637B (en) * 2011-01-17 2014-07-09 天津药物研究院 Peramivir hydrate crystal, preparation method, medical compound and usage thereof
CN102603577A (en) * 2011-01-19 2012-07-25 董慧珍 Derivatives of anti-influenza and anti-avian influenza medicament and application thereof
WO2012145932A1 (en) * 2011-04-29 2012-11-01 Pharmaresources (Shanghai) Co., Ltd. A novel process for the preparation of peramivir and intermediates thereof
CN102372657B (en) * 2011-11-14 2014-04-09 暨南大学 Synthesis method of anti-influenza and avian influenza virus resistant medicine peramivir
CN102863359B (en) * 2012-05-16 2014-05-07 常州制药厂有限公司 Synthesis method of anti-flu medicine
CN105085328B (en) * 2015-04-13 2018-06-29 广州南新制药有限公司 A kind of synthetic method of Peramivir trihydrate
CN108997171B (en) * 2018-06-21 2020-11-27 苏州正济医药研究有限公司 Synthetic method of 3+2 closed ring
CN113880732A (en) * 2021-10-12 2022-01-04 湖南凯铂生物药业有限公司 Peramivir impurity A and impurity C as well as preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
抗流感及禽流感新药帕拉米韦研究进展. 丘灵才等.中国兽药杂志,第40卷第6期. 2006
抗流感及禽流感新药帕拉米韦研究进展. 丘灵才等.中国兽药杂志,第40卷第6期. 2006 *

Also Published As

Publication number Publication date
CN1986521A (en) 2007-06-27

Similar Documents

Publication Publication Date Title
CN100432047C (en) Synthesis process of peramivir as medicine for antagonizing influenza and bird flu virus
US20250179111A1 (en) Method for synthesizing high-purity plant-derived cholesterol
CN101735140A (en) Chiral amino compound, method for synthesizing same and application of anti-flu medicament tamifiu intermediate thereof
US20250145658A1 (en) Synthesis method for high-purity cholesterol
CN103772193A (en) Method for preparing tricyclic derivatives
CN100522953C (en) Synthesis method of valsartan
CN106748966B (en) A kind of synthetic method of ramipril key intermediate
CN101407460A (en) Trihydroxy-2-acyl phenylacetate, and preparation and use thereof
CN105017181B (en) The preparation method of Carfilzomib key intermediate and its derivative
WO2007099843A1 (en) α,β-UNSATURATED CYCLOHEXANONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING INTERMEDIATE THEREFOR
CN103588833B (en) The preparation method of animal antibiotic tulathromycin
CN106278928B (en) A kind of synthetic method of Oseltamivir phosphate isomer impurities
CN101475573B (en) Anti-influenza medicament Tamiflu intermediate, synthesizing method and use thereof
JP6952974B2 (en) Method for producing amide compound
CN110981838B (en) 5-imine-tetrahydrofuryl methylamine derivative and preparation method and application thereof
CN103204810B (en) A kind of tolvaptan intermediate and preparation method thereof
CN106380418B (en) It is a kind of to use N-Methyl pyrrolidone/SOCl2The method for efficiently realizing ketoxime Beckmann rearrangement
CN102757399B (en) Preparation method of aliskiren intermediate
CN112142664A (en) A kind of synthetic method of polysubstituted naphthoazepine heterocyclic compounds
CN102757320B (en) Method for preparing aliskiren intermediate
CN102838609B (en) Azabicyclo [3.3.0] octane derivative, as well as preparation method and application thereof
KR101479986B1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
CN118146111A (en) Preparation method of oseltamium Wei Suanjia ester
CN103319482B (en) Method for synthesizing 1-hydroxymethyl-2-aza adamantane
CN102300839A (en) Method for manufacturing trans-{4-[(alkyl amino) methyl] cyclohexyl} acetic ester

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 510642 Guangdong city of Guangzhou province Tianhe District Wushan South China Agricultural University

Patentee after: South China Agricultural University

Patentee after: Guangdong Wens Foodstuff Group Co., Ltd.

Address before: 510642 Guangdong city of Guangzhou province Tianhe District Wushan South China Agricultural University

Patentee before: South China Agricultural University

Patentee before: Guangdong Wen's Food Group Co., Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 510000 No. 483 Wushan Road, Tianhe District, Guangzhou City, Guangdong Province

Co-patentee after: Winson food group Limited by Share Ltd

Patentee after: South China Agricultural University

Address before: 510642 South China Agricultural University, Tianhe District, Guangzhou, Guangdong

Co-patentee before: Guangdong Wens Foodstuff Group Co., Ltd.

Patentee before: South China Agricultural University